SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ellis MJ,Coop A,Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 38083816.
  • 2
    Kurokawa H,Lenferink AE,Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000; 60: 58875894.
  • 3
    Tokunaga E,Kimura Y,Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006; 13: 137144.
  • 4
    Jeng MH,Yue W,Eischeid A, et al. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat. 2000; 62: 167175.
  • 5
    O'Regan RM,Khuri FR. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocr Relat Cancer. 2004; 11: 191205.
  • 6
    Chen D,Washbrook E,Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by 2 distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002; 21: 49214931.
  • 7
    Knowlden JM,Hutcheson IR,Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003; 144: 10321044.
  • 8
    Johnston SRD,Lu B,Dowsett M, et al. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997; 57: 37233727.
  • 9
    Dowsett M,Nicholson RI,Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93:( suppl 1): S1118.
  • 10
    Martin LA,Farmer I,Johnston SR, et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003; 278: 3045830468.
  • 11
    Santen RJ,Song RX,Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer. 2005; 12( suppl 1): S6173.
  • 12
    Gradishar WJ,Chia S,Piccart-Gebhart MJ, et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat. 2006; 100. Abstract 12.
  • 13
    Johnston SRD,Saccani-Joti G,Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995; 55: 33813338.
  • 14
    Encarnacion CA,Ciocca DR,McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26: 237246.
  • 15
    Ottaviano YL,Issa JP,Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994; 54: 25522555.
  • 16
    Ferguson AT,Lapidus RG,Baylin SB,Davidson NE. Demethylation of estrogen receptor gene is estrogen receptor-negative breast cancer cells can re-activate estrogen receptor gene expression. Cancer Res. 1995; 55: 22792283.
  • 17
    Oh AS,Lorant LA,Holloway JN, et al. Hyperactivation of MAPK induces loss of ER-alpha expression in breast cancer cells. Mol Endocrinol. 2001; 15: 13441359.
  • 18
    Munzone E,Curigliano G,Rocca A, et al. Reverting estrogen-receptor negative phenotype in HER2 over-expressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res. 2006; 8: R4.
  • 19
    Gee JM,Harper ME,Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. 2003; 144: 51055117.
  • 20
    Mita M,De Bono J,Mita A, et al. A phase II and biologic correlative study investigating anastrozole in combination with gefitinib in post menopausal patients with estrogen receptor positive metastatic breast carcinoma who have previously failed hormonal therapy. Breast Cancer Res Treat. 2005; 94:( suppl 1). Abstract 1117.
  • 21
    Mayer I,Ganja N,Shyr Y,Muldowney N,Arteaga C. A phase II trial of letrozole plus erlotinib in post-menopausal women with hormone-sensitive metastatic breast cancer: preliminary results of toxicities and correlative studies. Breast Cancer Res Treat. 2006; 100:( suppl 1). Abstract 4052.
  • 22
    Smith IE,Welsh G,Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007; 25: 38163822.
  • 23
    Polychronis A,Sinnett HD,Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005; 6: 383391.
  • 24
    Klijn JG,Look MP,Portengen H, et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat. 1994; 29: 7383.
  • 25
    Atkins D,Reiffen KA,Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004; 52: 893901.
  • 26
    Massarweh S,Osborne CK,Jiang S, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor positive, HER2/neu positive breast cancer. Cancer Res. 2006; 82668273.
  • 27
    Marcom PK,Isaacs C,Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007; 102: 4349.
  • 28
    Vogel CL,Cobleigh MA,Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719726.
  • 29
    Mackey JR,Kaufman KB,Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2006; 100( suppl 1). Abstract 3.
  • 30
    Xia W,Bacus S,Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006; 103: 77957800.
  • 31
    Leary A,Lykkesfeldt A,Martin LA, et al. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in cell models of endocrine resistance. Breast Cancer Res Treat. 2006; 100( suppl 1). Abstract 303.
  • 32
    Chu Q,Rowinsky E,Goldstein LJ, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. Proc Am Soc Clin Oncol. 2005; 23. Abstract 3001.
  • 33
    Chu I,Blackwell K,Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005; 65: 1825.
  • 34
    Lipton A,Ali SM,Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003; 21: 19671972.
  • 35
    Clark GJ,Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 1995; 35: 133144.
  • 36
    Martin LA,Head JE,Pancholi S, et al. The farnesyl transferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cells proliferation and cell-cycle progression in-vitro and in-vivo. Mol Cancer Ther. 2007; 6: 24582467.
  • 37
    Dalenc F,Lacroix-Tikri M,Mourey L, et al. Tipifarnib with tamoxifen as a rescue for tamoxifen acquired clinical reistance for metastatic ER and/or PgR positive breast cancer after relapse under tamoxifen. Preliminary results. Breast Cancer Res Treat. 2005; 94:( suppl 1). Abstract 5098.
  • 38
    Lebowitz PF,Eng-Wong J,Widemann BC, et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res. 2005; 11: 12471252.
  • 39
    Johnston SRD,Semiglazov V,Manikhas G, et al on behalf of the R115777 INT-22 Investigators. A randomized, blinded, phase II study of tipifarnib (Zanestra) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 2007 (in press).
  • 40
    Appels NM,Beijnen JH,Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005; 10: 565578.
  • 41
    Wu G,Xing M,Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7: R609616.
  • 42
    Bachman KE,Argani P,Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004; 3: 772775.
  • 43
    Saal LH,Holm K,Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005; 65: 25542559.
  • 44
    Shoman N,Klassen S,McFadden A, et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol. 2005; 18: 250259.
  • 45
    Boulay A,Rudloff J,Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005; 11: 53195328.
  • 46
    Awada AC,Fontaine C,Dirix L, et al. A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (femara), investigating the safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. Breast Cancer Res Treat. 2004; 88:( suppl 1). Abstract 6043.
  • 47
    Baselga J,Roche H,Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res Treat. 2005; 94:( suppl 1). Abstract 1068.
  • 48
    Chow LWC,Shun Y,Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006; 100:( suppl 1). Abstract 6091.
  • 49
    Traina TA,Dickler MN,Caravelli SF, et al. A phase II trial of letrozole in combination with bevacizumab an anti-VEGF antibody in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2005; 94: ( suppl 1). Abstract 2030.